Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).

Jianming Xu(Chinese PLA General Hospital), Yanqi Wang(Peking University), Zhijun Wu(Nanjing Agricultural University), Chengxu Cui(Chinese Academy of Medical Sciences & Peking Union Medical College), Yan Wang(Stanford University), Yi Li(Chinese PLA General Hospital), Hui Zhou, Kangsheng Gu(Anhui Medical University), Xiuwen Wang(Second Hospital of Shandong University), Qingxia Fan(First Affiliated Hospital of Zhengzhou University), Zhuo Ma, Min Tao(Shanghai East Hospital), Linxinyu Xu, Tongjian Cui(Fujian Medical University), Tao Zhang(Jiangsu Hengrui Medicine (China)), Yunpeng Liu(Shenyang Institute of Automation), Juxiang Xiao(First Affiliated Hospital of Xi'an Jiaotong University), Quanli Gao(Zhengzhou University), Nong Xu(First Affiliated Hospital Zhejiang University), Yongqian Shu(Jiangsu Cancer Hospital)
Journal of Clinical Oncology
May 20, 2020
10.1200/jco.2020.38.15_suppl.4511
Cited by 24

Related Papers

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma
|JAMA|2021|821
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet|2023|701